Home Overweight & Obesity Overweight & Obesity Diseases COVID-19 and metabolic disease: mechanisms and clinical management

COVID-19 and metabolic disease: mechanisms and clinical management

0
COVID-19 and metabolic disease: mechanisms and clinical management


  • 1.
    • Clark A
    • Jit M
    • Warren-Gash C
    • et al.

    Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study.

    Lancet Glob Health. 2020; 8: e1003-e1017

  • 2.
    • Thakur B
    • Dubey P
    • Benitez J
    • et al.

    A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19.

    Sci Rep. 2021; 118562

  • 3.
    • Apicella M
    • Campopiano MC
    • Mantuano M
    • Mazoni L
    • Coppelli A
    • Del Prato S

    COVID-19 in people with diabetes: understanding the reasons for worse outcomes.

    Lancet Diabetes Endocrinol. 2020; 8: 782-792

  • 4.
    • Batabyal R
    • Freishtat N
    • Hill E
    • Rehman M
    • Freishtat R
    • Koutroulis I

    Metabolic dysfunction and immunometabolism in COVID-19 pathophysiology and therapeutics.

    Int J Obes. 2021; 45: 1163-1169

  • 5.
    • Costa FF
    • Rosário WR
    • Ribeiro Farias AC
    • de Souza RG
    • Duarte Gondim RS
    • Barroso WA

    Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies.

    Diabetes Metab Syndr. 2020; 14: 809-814

  • 6.
    • Docherty AB
    • Harrison EM
    • Green CA
    • et al.

    Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study.

    BMJ. 2020; 369m1985

  • 7.
    • Singh A
    • Hussain S
    • Antony B

    Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: a comprehensive systematic review and meta-analysis.

    Diabetes Metab Syndr. 2021; 15: 813-822

  • 8.
    • Singh AK
    • Gillies CL
    • Singh R
    • et al.

    Prevalence of co-morbidities and their association with mortality in patients with COVID-19: a systematic review and meta-analysis.

    Diabetes Obes Metab. 2020; 22: 1915-1924

  • 9.
    • Stefan N
    • Birkenfeld AL
    • Schulze MB

    Global pandemics interconnected – obesity, impaired metabolic health and COVID-19.

    Nat Rev Endocrinol. 2021; 17: 135-149

  • 10.
    • Kreutmair S
    • Unger S
    • Núñez NG
    • et al.

    Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia.

    Immunity. 2021; 54: 1578-1593

  • 11.
    • Kass DA
    • Duggal P
    • Cingolani O

    Obesity could shift severe COVID-19 disease to younger ages.

    Lancet. 2020; 395: 1544-1545

  • 12.
    • Bornstein SR
    • Rubino F
    • Ludwig B
    • et al.

    Consequences of the COVID-19 pandemic for patients with metabolic diseases.

    Nat Metab. 2021; 3: 289-292

  • 13.
    • Gregory JM
    • Slaughter JC
    • Duffus SH
    • et al.

    COVID-19 severity is tripled in the diabetes community: a prospective analysis of the pandemic’s impact in type 1 and type 2 diabetes.

    Diabetes Care. 2021; 44: 526-532

  • 14.
    • Ahmed F
    • Ahmed N
    • Pissarides C
    • Stiglitz J

    Why inequality could spread COVID-19.

    Lancet Public Health. 2020; 5: e240

  • 15.
    • Simpson AHR
    • Simpson CJ
    • Frost H
    • Welburn SC

    COVID-19: Obesity, deprivation and death.

    J Glob Health. 2020; 10020389

  • 16.
    • Brosh-Nissimov T
    • Orenbuch-Harroch E
    • Chowers M
    • et al.

    BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel.

    Clin Microbiol Infect. 2021; ()

  • 17.
    • Maestre-Muñiz MM
    • Arias Á
    • Mata-Vázquez E
    • et al.

    Long-term outcomes of patients with coronavirus disease 2019 at one year after hospital discharge.

    J Clin Med. 2021; 102945

  • 18.
    • Ramakrishnan RK
    • Kashour T
    • Hamid Q
    • Halwani R
    • Tleyjeh IM

    Unraveling the mystery surrounding post-acute sequelae of COVID-19.

    Front Immunol. 2021; 12686029

  • 19.
    • Simões e Silva AC
    • Silveira KD
    • Ferreira AJ
    • Teixeira MM

    ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis.

    Br J Pharmacol. 2013; 169: 477-492

  • 20.

    The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.

    Pharmacol Res. 2017; 125: 21-38

  • 21.
    • Coto E
    • Avanzas P
    • Gómez J

    The renin-angiotensin-aldosterone system and coronavirus disease 2019.

    Eur Cardiol. 2021; 16: e07

  • 22.
    • Bornstein SR
    • Rubino F
    • Khunti K
    • et al.

    Practical recommendations for the management of diabetes in patients with COVID-19.

    Lancet Diabetes Endocrinol. 2020; 8: 546-550

  • 23.

    Effects of taurine on ACE, ACE2 and HSP70 expression of hypothalamic-pituitary-adrenal axis in stress-induced hypertensive rats.

    Adv Exp Med Biol. 2017; 975: 871-886

  • 24.
    • Coate KC
    • Cha J
    • Shrestha S
    • et al.

    SARS-CoV-2 cell entry factors ACE2 and TMPRSS2 are expressed in the microvasculature and ducts of human pancreas but are not enriched in β cells.

    Cell Metab. 2020; 32: 1028-1040.e4

  • 25.
    • Kusmartseva I
    • Wu W
    • Syed F
    • et al.

    Expression of SARS-CoV-2 entry factors in the pancreas of normal organ donors and individuals with COVID-19.

    Cell Metab. 2020; 32: 1041-1051.e6

  • 26.
    • Liu F
    • Long X
    • Zhang B
    • Zhang W
    • Chen X
    • Zhang Z

    ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection.

    Clin Gastroenterol Hepatol. 2020; 18: 2128-2130.e2

  • 27.
    • Fignani D
    • Licata G
    • Brusco N
    • et al.

    SARS-CoV-2 receptor angiotensin I-converting enzyme type 2 (ACE2) is expressed in human pancreatic β-cells and in the human pancreas microvasculature.

    Front Endocrinol (Lausanne). 2020; 11596898

  • 28.
    • Müller JA
    • Groß R
    • Conzelmann C
    • et al.

    SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas.

    Nat Metab. 2021; 3: 149-165

  • 29.
    • Wu CT
    • Lidsky PV
    • Xiao Y
    • et al.

    SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment.

    Cell Metab. 2021; 33: 1565-1576.e5

  • 30.
    • Steenblock C
    • Richter S
    • Berger I
    • et al.

    Viral infiltration of pancreatic islets in patients with COVID-19.

    Nat Commun. 2021; 123534

  • 31.
    • Kumar A
    • Faiq MA
    • Pareek V
    • et al.

    Relevance of SARS-CoV-2 related factors ACE2 and TMPRSS2 expressions in gastrointestinal tissue with pathogenesis of digestive symptoms, diabetes-associated mortality, and disease recurrence in COVID-19 patients.

    Med Hypotheses. 2020; 144110271

  • 32.
    • Young MJ
    • Clyne CD
    • Chapman KE

    Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2.

    J Endocrinol. 2020; 247: R45-R62

  • 33.
    • Fang L
    • Karakiulakis G
    • Roth M

    Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?.

    Lancet Respir Med. 2020; 8: e21

  • 34.
    • Horby P
    • Lim WS
    • Emberson JR
    • et al.

    Dexamethasone in hospitalized patients with COVID-19.

    N Engl J Med. 2021; 384: 693-704

  • 35.
    • Esguerra JLS
    • Ofori JK
    • Nagao M
    • et al.

    Glucocorticoid induces human beta cell dysfunction by involving riborepressor GAS5 LincRNA.

    Mol Metab. 2020; 32: 160-167

  • 36.

    A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

    Eur Heart J Cardiovasc Pharmacother. 2021; 7: 148-157

  • 37.

    Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig.

    Nat Commun. 2020; 112070

  • 38.
    • Bouhanick B
    • Cracowski JL
    • Faillie JL

    DPP-4 inhibitors and severe course of illness in patients with COVID-19.

    Therapie. 2021; 76: 359-360

  • 39.
    • Samuel SM
    • Varghese E
    • Büsselberg D

    Therapeutic potential of metformin in COVID-19: reasoning for its protective role.

    Trends Microbiol. 2021; ()

  • 40.
    • Khunti K
    • Knighton P
    • Zaccardi F
    • et al.

    Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England.

    Lancet Diabetes Endocrinol. 2021; 9: 293-303

  • 41.

    Anti-inflammatory properties of antidiabetic drugs: a “promised land” in the COVID-19 era?.

    J Diabetes Complications. 2020; 34107723

  • 42.
    • Nohara H
    • Nakashima R
    • Kamei S
    • et al.

    Intratracheal GLP-1 receptor agonist treatment up-regulates mucin via p38 and exacerbates emphysematous phenotype in mucus hypersecretory obstructive lung diseases.

    Biochem Biophys Res Commun. 2020; 524: 332-339

  • 43.
    • Pal R
    • Banerjee M
    • Mukherjee S
    • Bhogal RS
    • Kaur A
    • Bhadada SK

    Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis.

    Ther Adv Endocrinol Metab. 2021; 12 ()

  • 44.
    • Rhee SY
    • Lee J
    • Nam H
    • Kyoung DS
    • Shin DW
    • Kim DJ

    Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19.

    Diabetes Metab J. 2021; 45: 251-259

  • 45.
    • Stumpf J
    • Siepmann T
    • Lindner T
    • et al.

    Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine.

    Lancet Reg Health Eur. 2021; ()

  • 46.

    Diabetes, obesity, COVID-19, Insulin, and other antidiabetes drugs.

    Diabetes Care. 2021; 44: 1929-1933

  • 47.

    Insulin treatment is associated with increased mortality in patients with COVID-19 and type 2 diabetes.

    Cell Metab. 2021; 33: 65-77

  • 48.
    • Mancia G
    • Rea F
    • Ludergnani M
    • Apolone G
    • Corrao G

    Renin-angiotensin-aldosterone system blockers and the risk of COVID-19.

    N Engl J Med. 2020; 382: 2431-2440

  • 49.
    • Mehta N
    • Kalra A
    • Nowacki AS
    • et al.

    Association of use of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers with testing positive for coronavirus disease 2019 (COVID-19).

    JAMA Cardiol. 2020; 5: 1020-1026

  • 50.
    • Zhang P
    • Zhu L
    • Cai J
    • et al.

    Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19.

    Circ Res. 2020; 126: 1671-1681

  • 51.
    • Villard O
    • Morquin D
    • Molinari N
    • et al.

    The plasmatic aldosterone and c-reactive protein levels, and the severity of COVID-19: the Dyhor-19 study.

    J Clin Med. 2020; 9E2315

  • 52.
    • Hoffmann M
    • Kleine-Weber H
    • Schroeder S
    • et al.

    SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.

    Cell. 2020; 181: 271-280.e8

  • 53.
    • Walls AC
    • Park YJ
    • Tortorici MA
    • Wall A
    • McGuire AT
    • Veesler D

    Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein.

    Cell. 2020; 181: 281-292.e6

  • 54.
    • Davies NG
    • Abbott S
    • Barnard RC
    • et al.

    Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.

    Science. 2021; 372eabg3055

  • 55.
    • Faria NR
    • Mellan TA
    • Whittaker C
    • et al.

    Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil.

    Science. 2021; 372: 815-821

  • 56.
    • Leung K
    • Shum MH
    • Leung GM
    • Lam TT
    • Wu JT

    Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020.

    Euro Surveill. 2021; 262002106

  • 57.
    • Khan A
    • Zia T
    • Suleman M
    • et al.

    Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: an insight from structural data.

    J Cell Physiol. 2021; 236: 7045-7057

  • 58.
    • Alai S
    • Gujar N
    • Joshi M
    • Gautam M
    • Gairola S

    Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein.

    Heliyon. 2021; 7e06564

  • 59.

    Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.

    Nature. 2020; 581: 215-220

  • 60.
    • Cantuti-Castelvetri L
    • Ojha R
    • Pedro LD
    • et al.

    Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity.

    Science. 2020; 370: 856-860

  • 61.
    • Wei J
    • Alfajaro MM
    • DeWeirdt PC
    • et al.

    Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection.

    Cell. 2021; 184: 76-91

  • 62.
    • Karki R
    • Sharma BR
    • Tuladhar S
    • et al.

    Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes.

    Cell. 2021; 184: 149-168

  • 63.
    • Nakamura H
    • Kinjo T
    • Arakaki W
    • Miyagi K
    • Tateyama M
    • Fujita J

    Serum levels of receptor-interacting protein kinase-3 in patients with COVID-19.

    Crit Care. 2020; 24: 484

  • 64.
    • Linkermann A
    • Stockwell BR
    • Krautwald S
    • Anders HJ

    Regulated cell death and inflammation: an auto-amplification loop causes organ failure.

    Nat Rev Immunol. 2014; 14: 759-767

  • 65.
    • Li Y
    • Zhang Z
    • Yang L
    • et al.

    The MERS-CoV Receptor DPP4 as a candidate binding target of the SARS-CoV-2 spike.

    iScience. 2020; 23101160

  • 66.
    • Lambeir AM
    • Durinx C
    • Scharpé S
    • De Meester I

    Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.

    Crit Rev Clin Lab Sci. 2003; 40: 209-294

  • 67.

    Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors.

    Endocr Rev. 2014; 35: 992-1019

  • 68.

    Coronavirus Infections and type 2 diabetes-shared pathways with therapeutic implications.

    Endocr Rev. 2020; 41bnaa011

  • 69.
    • Seidu S
    • Gillies C
    • Zaccardi F
    • et al.

    The impact of obesity on severe disease and mortality in people with SARS-CoV-2: a systematic review and meta-analysis.

    Endocrinol Diabetes Metab. 2020; 4e00176

  • 70.

    A metabolic handbook for the COVID-19 pandemic.

    Nat Metab. 2020; 2: 572-585

  • 71.

    Causes, consequences, and treatment of metabolically unhealthy fat distribution.

    Lancet Diabetes Endocrinol. 2020; 8: 616-627

  • 72.

    COVID-19 and the heart.

    Circ Res. 2020; 126: 1443-1455

  • 73.
    • Avula A
    • Nalleballe K
    • Narula N
    • et al.

    COVID-19 presenting as stroke.

    Brain Behav Immun. 2020; 87: 115-119

  • 74.
    • Boucher J
    • Kleinridders A
    • Kahn CR

    Insulin receptor signaling in normal and insulin-resistant states.

    Cold Spring Harb Perspect Biol. 2014; 6a009191

  • 75.
    • Amin MN
    • Hussain MS
    • Sarwar MS
    • et al.

    How the association between obesity and inflammation may lead to insulin resistance and cancer.

    Diabetes Metab Syndr. 2019; 13: 1213-1224

  • 76.
    • Lauterbach MA
    • Wunderlich FT

    Macrophage function in obesity-induced inflammation and insulin resistance.

    Pflugers Arch. 2017; 469: 385-396

  • 77.
    • Santos A
    • Magro DO
    • Evangelista-Poderoso R
    • Saad MJA

    Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications.

    Diabetol Metab Syndr. 2021; 13: 23

  • 78.
    • Sindhu S
    • Thomas R
    • Shihab P
    • Sriraman D
    • Behbehani K
    • Ahmad R

    Obesity is a positive modulator of IL-6R and IL-6 expression in the subcutaneous adipose tissue: significance for metabolic inflammation.

    PLoS One. 2015; 10e0133494

  • 79.
    • Esser N
    • Legrand-Poels S
    • Piette J
    • Scheen AJ
    • Paquot N

    Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes.

    Diabetes Res Clin Pract. 2014; 105: 141-150

  • 80.
    • Schwarz PEH
    • Timpel P
    • Harst L
    • et al.

    Blood sugar regulation for cardiovascular health promotion and disease prevention: JACC health promotion series.

    J Am Coll Cardiol. 2018; 72: 1829-1844

  • 81.
    • Marx C
    • Ehrhart-Bornstein M
    • Scherbaum WA
    • Bornstein SR

    Regulation of adrenocortical function by cytokines–relevance for immune-endocrine interaction.

    Horm Metab Res. 1998; 30: 416-420

  • 82.
    • Steenblock C
    • Todorov V
    • Kanczkowski W
    • et al.

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the neuroendocrine stress axis.

    Mol Psychiatry. 2020; 25: 1611-1617

  • 83.
    • Ramakrishnan S
    • Nicolau Jr, DV
    • Langford B
    • et al.

    Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.

    Lancet Respir Med. 2021; 9: 763-772

  • 84.
    • Isidori AM
    • Pofi R
    • Hasenmajer V
    • Lenzi A
    • Pivonello R

    Use of glucocorticoids in patients with adrenal insufficiency and COVID-19 infection.

    Lancet Diabetes Endocrinol. 2020; 8: 472-473

  • 85.
    • Conti P
    • Ronconi G
    • Caraffa A
    • et al.

    Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.

    J Biol Regul Homeost Agents. 2020; 34: 327-331

  • 86.
    • Alsadhan I
    • Alruwashid S
    • Alhamad M
    • et al.

    Diabetic ketoacidosis precipitated by Coronavirus disease 2019 infection: case series.

    Curr Ther Res Clin Exp. 2020; 93100609

  • 87.
    • Heaney AI
    • Griffin GD
    • Simon EL

    Newly diagnosed diabetes and diabetic ketoacidosis precipitated by COVID-19 infection.

    Am J Emerg Med. 2020; 38: 2491e3-2491e4

  • 88.
    • Hollstein T
    • Schulte DM
    • Schulz J
    • et al.

    Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report.

    Nat Metab. 2020; 2: 1021-1024

  • 89.
    • Li J
    • Wang X
    • Chen J
    • Zuo X
    • Zhang H
    • Deng A

    COVID-19 infection may cause ketosis and ketoacidosis.

    Diabetes Obes Metab. 2020; 22: 1935-1941

  • 90.
    • Montefusco L
    • Ben Nasr M
    • D’Addio F
    • et al.

    Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection.

    Nat Metab. 2021; 3: 774-785

  • 91.
    • Naguib MN
    • Raymond JK
    • Vidmar AP

    New onset diabetes with diabetic ketoacidosis in a child with multisystem inflammatory syndrome due to COVID-19.

    J Pediatr Endocrinol Metab. 2020; 34: 147-150

  • 92.
    • Rubino F
    • Amiel SA
    • Zimmet P
    • et al.

    New-onset diabetes in COVID-19.

    N Engl J Med. 2020; 383: 789-790

  • 93.
    • Kamrath C
    • Mönkemöller K
    • Biester T
    • et al.

    Ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the COVID-19 pandemic in Germany.

    JAMA. 2020; 324: 801-804

  • 94.
    • Salmi H
    • Heinonen S
    • Hästbacka J
    • et al.

    New-onset type 1 diabetes in Finnish children during the COVID-19 pandemic.

    Arch Dis Child. 2021; ()

  • 95.
    • Kumaran NK
    • Karmakar BK
    • Taylor OM

    Coronavirus disease-19 (COVID-19) associated with acute necrotising pancreatitis (ANP).

    BMJ Case Rep. 2020; 13e237903

  • 96.

    Can COVID-19 cause diabetes?.

    Nat Metab. 2021; 3: 123-125

  • 97.
    • Bailey B
    • Whelen ML
    • Strunk DR

    Adhering to COVID-19 health guidelines: examining demographic and psychological predictors of adherence.

    Appl Psychol Health Well-Being. 2021; ()

  • 98.

    COVID-19 vaccination in patients with diabetes mellitus: current concepts, uncertainties and challenges.

    Diabetes Metab Syndr. 2021; 15: 505-508

  • 99.
    • McGovern AP
    • Thomas NJ
    • Vollmer SJ
    • Hattersley AT
    • Mateen BA
    • Dennis JM

    The disproportionate excess mortality risk of COVID-19 in younger people with diabetes warrants vaccination prioritisation.

    Diabetologia. 2021; 64: 1184-1186

  • 100.
    • Müller G
    • Weser G
    • Schwarz PE

    The European perspective of diabetes prevention: the need for individualization of diabetes prevention.

    J Endocrinol Invest. 2013; 36: 352-357

  • 101.
    • Royal Australian College of General Practitioners

    Diabetes management during coronavirus.

  • 102.
    • Quinn LM
    • Davies MJ
    • Northern A
    • et al.

    Use of MyDesmond digital education programme to support self-management in people with type 2 diabetes during the COVID-19 pandemic.

    Diabet Med. 2021; 38e14469

  • 103.
    • Rogers LC
    • Snyder RJ
    • Joseph WS

    Diabetes-related amputations: a pandemic within a pandemic.

    J Am Podiatr Med Assoc. 2020; ()

  • 104.

    Serum hypoglycemia.

  • 105.
    • Chudasama YV
    • Gillies CL
    • Zaccardi F
    • et al.

    Impact of COVID-19 on routine care for chronic diseases: a global survey of views from healthcare professionals.

    Diabetes Metab Syndr. 2020; 14: 965-967

  • 106.
    • Rowlands AV
    • Henson JJ
    • Coull NA
    • et al.

    The impact of COVID-19 restrictions on accelerometer-assessed physical activity and sleep in individuals with type 2 diabetes.

    Diabet Med. 2021; ()

  • 107.
    • Gregg EW
    • Sophiea MK
    • Weldegiorgis M

    Diabetes and COVID-19: population impact 18 months into the pandemic.

    Diabetes Care. 2021; 44: 1916-1923

  • 108.
    • McGurnaghan SJ
    • Weir A
    • Bishop J
    • et al.

    Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland.

    Lancet Diabetes Endocrinol. 2021; 9: 82-93

  • 109.
    • Petrie JR
    • Boyle JG
    • Ali K
    • Smith C
    • Morrison D
    • Kar P

    A post COVID-19 ‘Marshall Plan’ for type 2 diabetes.

    Diabet Med. 2021; 38e14439

  • 110.
    • Cyranka K
    • Dudek D
    • Małecki MT
    • Matejko B
    • Klupa T

    Psychological crisis intervention for COVID-19 lockdown stress in patients with type 1 diabetes mellitus: survey study and qualitative analysis.

    JMIR Ment Health. 2021; 8e28097

  • 111.
    • Ruissen MM
    • Regeer H
    • Landstra CP
    • et al.

    Increased stress, weight gain and less exercise in relation to glycemic control in people with type 1 and type 2 diabetes during the COVID-19 pandemic.

    BMJ Open Diabetes Res Care. 2021; 9e002035

  • 112.
    • Ruberti OM
    • Telles GD
    • Rodrigues B

    Stress and physical inactivity: two explosive ingredients for the heart in COVID-19 pandemic times.

    Curr Cardiol Rev. 2021; ()

  • 113.
    • Ceriello A
    • Prattichizzo F

    Pharmacological management of COVID-19 in type 2 diabetes.

    J Diabetes Complications. 2021; 35107927

  • 114.
    • Kosiborod MN
    • Esterline R
    • Furtado RHM
    • et al.

    Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Lancet Diabetes Endocrinol. 2021; 9: 586-594

  • 115.
    • Cariou B
    • Pichelin M
    • Goronflot T
    • et al.

    Phenotypic characteristics and prognosis of newly diagnosed diabetes in hospitalized patients with COVID-19: results from the CORONADO study.

    Diabetes Res Clin Pract. 2021; 175108695

  • 116.
    • Noh Y
    • Oh IS
    • Jeong HE
    • Filion KB
    • Yu OHY
    • Shin JY

    Association between DPP-4 inhibitors and COVID-19-related outcomes among patients with type 2 diabetes.

    Diabetes Care. 2021; 44: e64-e66

  • 117.
    • Solerte SB
    • D’Addio F
    • Trevisan R
    • et al.

    Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and covid-19: a multicenter, case-control, retrospective, observational study.

    Diabetes Care. 2020; 43: 2999-3006

  • 118.

    Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: a meta-analysis.

    J Med Virol. 2021; 93: 695-697

  • 119.

    Metformin and COVID-19: from cellular mechanisms to reduced mortality.

    Diabetes Metab. 2020; 46: 423-426

  • 120.
    • Cheng X
    • Liu YM
    • Li H
    • et al.

    Metformin is associated with higher incidence of acidosis, but not mortality, in individuals with COVID-19 and pre-existing type 2 diabetes.

    Cell Metab. 2020; 32: 537-547

  • 121.

    Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

    Lancet. 2021; 397: 1637-1645

  • 122.
    • Castañeda S
    • Remuzgo-Martínez S
    • López-Mejías R
    • et al.

    Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis.

    Clin Exp Rheumatol. 2019; 37: 465-473

  • 123.
    • Marfella R
    • Paolisso P
    • Sardu C
    • et al.

    Negative impact of hyperglycaemia on tocilizumab therapy in COVID-19 patients.

    Diabetes Metab. 2020; 46: 403-405

  • 124.
    • Katulanda P
    • Dissanayake HA
    • Ranathunga I
    • et al.

    Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature.

    Diabetologia. 2020; 63: 1440-1452

  • 125.
    • Sterne JAC
    • Murthy S
    • et al.
    • Group WHOREAfC-TW

    Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: meta-analysis A.

    JAMA. 2020; 324: 1330-1341

  • 126.
    • Perez A
    • Jansen-Chaparro S
    • Saigi I
    • Bernal-Lopez MR
    • Miñambres I
    • Gomez-Huelgas R

    Glucocorticoid-induced hyperglycemia.

    J Diabetes. 2014; 6: 9-20

  • 127.
    • American Diabetes Association

    FDA expands remote patient monitoring in hospitals for people with diabetes during COVID-19; manufacturers donate CGM supplies.

  • 128.
    • Zhu L
    • She ZG
    • Cheng X
    • et al.

    Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes.

    Cell Metab. 2020; 31: 1068-1077

  • 129.
    • Klonoff DC
    • Messler JC
    • Umpierrez GE
    • et al.

    Association between achieving inpatient glycemic control and clinical outcomes in hospitalized patients with COVID-19: a multicenter, retrospective hospital-based analysis.

    Diabetes Care. 2021; 44: 578-585

  • 130.
    • Lu J
    • Wang C
    • Shen Y
    • et al.

    Time in range in relation to all-cause and cardiovascular mortality in patients with type 2 diabetes: a prospective cohort study.

    Diabetes Care. 2021; 44: 549-555

  • 131.

    Altered lipid metabolism in recovered SARS patients twelve years after infection.

    Sci Rep. 2017; 79110

  • 132.
    • Yang JK
    • Lin SS
    • Ji XJ
    • Guo LM

    Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes.

    Acta Diabetol. 2010; 47: 193-199

  • 133.

    Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study.

    BMC Neurol. 2011; 11: 37

  • 134.

    COVID-19 and chronic fatigue syndrome: is the worst yet to come?.

    Med Hypotheses. 2021; 146110469

  • 135.

    High-dimensional characterization of post-acute sequelae of COVID-19.

    Nature. 2021; 594: 259-264

  • 136.
    • Barker-Davies RM
    • O’Sullivan O
    • Senaratne KPP
    • et al.

    The Stanford Hall consensus statement for post-COVID-19 rehabilitation.

    Br J Sports Med. 2020; 54: 949-959

  • 137.
    • Berger I
    • Werdermann M
    • Bornstein SR
    • Steenblock C

    The adrenal gland in stress – adaptation on a cellular level.

    J Steroid Biochem Mol Biol. 2019; 190: 198-206

  • 138.
    • Rohr M
    • Weiß A
    • Bein T
    • et al.

    Experiences, opinions and expectations of health care providers towards an intensive care unit follow-up clinic: Qualitative study and online survey.

    Intensive Crit Care Nurs. 2021; ()

  • 139.

    Mucormycosis.

    Infect Dis Clin North Am. 2021; 35: 435-452

  • 140.
    • Sharma S
    • Grover M
    • Bhargava S
    • Samdani S
    • Kataria T

    Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum.

    J Laryngol Otol. 2021; 135: 442-447

  • 141.
    • Khunti K
    • Davies MJ
    • Kosiborod MN
    • Nauck MA

    Long COVID – metabolic risk factors and novel therapeutic management.

    Nat Rev Endocrinol. 2021; 17: 379-380

  • 142.
    • Ayoubkhani D
    • Khunti K
    • Nafilyan V
    • et al.

    Post-COVID syndrome in individuals admitted to hospital with COVID-19: retrospective cohort study.

    BMJ. 2021; 372: n693

  • 143.
    • Correr CJ
    • Coura-Vital W
    • Frade JCQP
    • et al.

    Prevalence of people at risk of developing type 2 diabetes mellitus and the involvement of community pharmacies in a national screening campaign: a pioneer action in Brazil.

    Diabetol Metab Syndr. 2020; 12: 89

  • 144.
    • Mehta SR
    • Kashyap AS
    • Das S

    Diabetes mellitus in India: the modern scourge.

    Med J Armed Forces India. 2009; 65: 50-54

  • 145.
    • Satman I
    • Omer B
    • Tutuncu Y
    • et al.

    Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults.

    Eur J Epidemiol. 2013; 28: 169-180

  • 146.

    Coronavirus in Africa: five reasons why COVID-19 has been less deadly than elsewhere.

  • 147.
    • Timpel P
    • Harst L
    • Reifegerste D
    • Weihrauch-Blüher S
    • Schwarz PEH

    What should governments be doing to prevent diabetes throughout the life course?.

    Diabetologia. 2019; 62: 1842-1853

  • 148.
    • Jose T
    • Warner DO
    • O’Horo JC
    • et al.

    Digital health surveillance strategies for management of coronavirus disease 2019.

    Mayo Clin Proc Innov Qual Outcomes. 2021; 5: 109-117

  • 149.
    • Deckert A
    • Anders S
    • de Allegri M
    • et al.

    Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.

    Trials. 2021; 22: 39

  • 150.

    A quantitative estimation of the pancreatic islet tissue1.

    QJM. 1937; 6: 287-300

  • 151.
    • Jacob L
    • Rickwood S
    • Rathmann W
    • Kostev K

    Change in glucose-lowering medication regimens in individuals with type 2 diabetes mellitus during the COVID-19 pandemic in Germany.

    Diabetes Obes Metab. 2021; 23: 910-915

  • 152.
    • Chan JCN
    • Lim LL
    • Wareham NJ
    • et al.

    The Lancet Commission on diabetes: using data to transform diabetes care and patient lives.

    Lancet. 2021; 396: 2019-2082



  • Source link

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here

    For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

    I agree to these terms.

    en English
    X